Perrigo Company plc Operating Income
Perrigo Company plc (PRGO) reported Operating Income of $23.50 million for the 3-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- Perrigo Company plc operating income (loss) for the quarter ending 2026-06-27 was $23.50M, a 48.24% decline year-over-year.
- Perrigo Company plc operating income (loss) for the quarter ending 2026-03-28 was -$372.30M, a 893.82% decline year-over-year.
- Perrigo Company plc operating income (loss) for the quarter ending 2025-12-31 was -$1.29B, a 1227.06% decline year-over-year.
- Perrigo Company plc operating income (loss) for the quarter ending 2025-09-27 was $72.60M, a 9.70% decline year-over-year.
- Perrigo Company plc operating income (loss) for fiscal 2025 was -$1.12B, a 1093.98% decline from fiscal 2024.
- Perrigo Company plc operating income (loss) for fiscal 2024 was $112.90M, a 25.67% decline from fiscal 2023.
- Perrigo Company plc operating income (loss) for fiscal 2023 was $151.90M, a 92.52% increase from fiscal 2022.
- Perrigo Company plc operating income (loss) for fiscal 2022 was $78.90M, a 80.77% decline from fiscal 2021.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-27 | $23.50M 10-Q · filed 2026-08-05 | -$348.90M 10-Q · filed 2026-08-05 | -$1.64B derived: sum of 3 quarters · filed 2026-08-05 | -$1.56B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-28 | -$372.30M 10-Q · filed 2026-05-06 | -$1.66B derived: sum of 2 quarters · filed 2026-05-06 | -$1.59B derived: sum of 3 quarters · filed 2026-05-06 | -$1.54B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | -$1.29B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$1.21B derived: sum of 2 quarters · filed 2026-02-26 | -$1.17B derived: sum of 3 quarters · filed 2026-08-05 | -$1.12B 10-K · filed 2026-02-26 | ||||
| 2025-09-27 | $72.60M 10-Q · filed 2025-11-05 | $118.00M derived: sum of 2 quarters · filed 2026-08-05 | $164.90M 10-Q · filed 2025-11-05 | $279.10M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-28 | $45.40M 10-Q · filed 2026-08-05 | $92.30M 10-Q · filed 2026-08-05 | $206.50M derived: sum of 3 quarters · filed 2026-08-05 | $286.90M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-29 | $46.90M 10-Q · filed 2026-05-06 | $161.10M derived: sum of 2 quarters · filed 2026-05-06 | $241.50M derived: sum of 3 quarters · filed 2026-05-06 | $215.00M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $114.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $194.60M derived: sum of 2 quarters · filed 2026-02-26 | $168.10M derived: sum of 3 quarters · filed 2026-02-26 | $112.90M 10-K · filed 2026-02-26 | ||||
| 2024-09-28 | $80.40M 10-Q · filed 2025-11-05 | $53.90M derived: sum of 2 quarters · filed 2025-11-05 | -$1.30M 10-Q · filed 2025-11-05 | -$16.90M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-29 | -$26.50M 10-Q · filed 2025-08-06 | -$81.70M 10-Q · filed 2025-08-06 | -$97.30M derived: sum of 3 quarters · filed 2026-02-26 | -$35.20M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-30 | -$55.20M 10-Q · filed 2025-05-07 | -$70.80M derived: sum of 2 quarters · filed 2026-02-26 | -$8.70M derived: sum of 3 quarters · filed 2026-02-26 | $48.10M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | -$15.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $46.50M derived: sum of 2 quarters · filed 2026-02-26 | $103.30M derived: sum of 3 quarters · filed 2026-02-26 | $151.90M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $62.10M 10-Q · filed 2024-11-06 | $118.90M derived: sum of 2 quarters · filed 2024-11-06 | $167.50M 10-Q · filed 2024-11-06 | $198.40M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-07-01 | $56.80M 10-Q · filed 2024-08-02 | $105.40M 10-Q · filed 2024-08-02 | $136.30M derived: sum of 3 quarters · filed 2025-02-28 | $169.40M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-04-01 | $48.50M 10-Q · filed 2024-05-07 | $79.50M derived: sum of 2 quarters · filed 2025-02-28 | $112.60M derived: sum of 3 quarters · filed 2025-02-28 | $105.70M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2022-12-31 | $31.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $64.10M derived: sum of 2 quarters · filed 2025-02-28 | $57.20M derived: sum of 3 quarters · filed 2025-02-28 | $78.90M 10-K · filed 2025-02-28 | ||||
| 2022-10-01 | $33.10M 10-Q · filed 2023-11-07 | $26.20M derived: sum of 2 quarters · filed 2023-11-07 | $47.90M 10-Q · filed 2023-11-07 | $94.60M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-07-02 | -$6.90M 10-Q · filed 2023-08-08 | $14.80M 10-Q · filed 2023-08-08 | $61.50M derived: sum of 3 quarters · filed 2024-02-27 | $499.80M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-04-02 | $21.70M 10-Q · filed 2023-05-09 | $68.40M derived: sum of 2 quarters · filed 2024-02-27 | $506.70M derived: sum of 3 quarters · filed 2024-02-27 | $380.80M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | $46.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $485.00M derived: sum of 2 quarters · filed 2024-02-27 | $359.10M derived: sum of 3 quarters · filed 2024-02-27 | $410.40M 10-K · filed 2024-02-27 | ||||
| 2021-10-02 | $438.30M 10-Q · filed 2022-11-08 | $312.40M derived: sum of 2 quarters · filed 2022-11-08 | $363.70M 10-Q · filed 2022-11-08 | $401.40M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-07-03 | -$125.90M 10-Q · filed 2022-08-09 | -$74.60M 10-Q · filed 2022-08-09 | -$36.90M derived: sum of 3 quarters · filed 2023-02-28 | $41.60M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-04-03 | $51.40M 10-Q · filed 2022-05-11 | $89.00M derived: sum of 2 quarters · filed 2023-02-28 | $167.50M derived: sum of 3 quarters · filed 2023-02-28 | $230.20M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $37.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $116.10M derived: sum of 2 quarters · filed 2023-02-28 | $178.80M derived: sum of 3 quarters · filed 2023-02-28 | $265.20M 10-K · filed 2023-02-28 | $115.40M 10-K · filed 2021-03-01 | |||
| 2020-09-26 | $78.50M 10-Q · filed 2021-11-12 | -$95.50M 10-Q · filed 2020-11-05 | $141.20M derived: sum of 2 quarters · filed 2021-11-12 | $227.60M 10-Q · filed 2021-11-12 | $167.60M 10-Q · filed 2020-11-05 | $190.60M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-27 | $62.70M 10-Q · filed 2021-08-11 | $117.40M 10-Q · filed 2020-08-05 | $149.10M 10-Q · filed 2021-08-11 | $263.10M 10-Q · filed 2020-08-05 | $112.10M derived: sum of 3 quarters · filed 2022-03-01 | $166.50M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-28 | $86.40M 10-Q · filed 2021-05-12 | $145.70M 10-Q · filed 2020-05-05 | $49.40M derived: sum of 2 quarters · filed 2022-03-01 | $103.80M derived: sum of 3 quarters · filed 2022-03-01 | $158.80M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | -$37.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $17.40M derived: sum of 2 quarters · filed 2022-03-01 | $72.40M derived: sum of 3 quarters · filed 2022-03-01 | $174.70M 10-K · filed 2022-03-01 | $204.80M 10-K · filed 2020-02-27 | |||
| 2019-09-28 | $54.40M 10-Q · filed 2020-11-05 | $109.40M derived: sum of 2 quarters · filed 2020-11-05 | $211.70M 10-Q · filed 2020-11-05 | $319.20M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-29 | $55.00M 10-Q · filed 2020-08-05 | $157.30M 10-Q · filed 2020-08-05 | $264.80M derived: sum of 3 quarters · filed 2021-03-01 | $142.80M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-30 | $102.30M 10-Q · filed 2020-05-05 | $209.80M derived: sum of 2 quarters · filed 2021-03-01 | $87.80M derived: sum of 3 quarters · filed 2021-03-01 | $182.50M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $107.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$14.50M derived: sum of 2 quarters · filed 2021-03-01 | $80.20M derived: sum of 3 quarters · filed 2021-03-01 | $236.50M 10-K · filed 2021-03-01 | ||||
| 2018-09-29 | -$122.00M 10-Q · filed 2019-11-06 | -$27.30M derived: sum of 2 quarters · filed 2019-11-06 | $129.00M 10-Q · filed 2019-11-06 | $287.60M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-06-30 | $94.70M 10-Q · filed 2019-08-08 | $250.90M 10-Q · filed 2019-08-08 | $409.60M derived: sum of 3 quarters · filed 2020-02-27 | $572.00M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-03-31 | $156.30M 10-Q · filed 2019-05-09 | $314.90M derived: sum of 2 quarters · filed 2020-02-27 | $477.30M derived: sum of 3 quarters · filed 2020-02-27 | $626.10M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2017-12-31 | $158.60M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $321.00M derived: sum of 2 quarters · filed 2020-02-27 | $469.80M derived: sum of 3 quarters · filed 2020-02-27 | $598.20M 10-K · filed 2020-02-27 | ||||
| 2017-09-30 | $162.40M 10-Q · filed 2018-11-08 | $311.20M derived: sum of 2 quarters · filed 2018-11-08 | $439.60M 10-Q · filed 2018-11-08 | -$44.90M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-07-01 | $148.80M 10-Q · filed 2018-08-09 | $277.30M 10-Q · filed 2018-08-09 | -$207.30M derived: sum of 3 quarters · filed 2019-02-27 | -$1.68B derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-04-01 | $128.50M 10-Q · filed 2018-05-08 | -$356.10M derived: sum of 2 quarters · filed 2019-02-27 | -$1.82B derived: sum of 3 quarters · filed 2019-02-27 | -$1.64B derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2016-12-31 | -$484.60M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$1.95B derived: sum of 2 quarters · filed 2019-02-27 | -$1.77B derived: sum of 3 quarters · filed 2019-02-27 | -$2.00B 10-K · filed 2019-02-27 | ||||
| 2016-10-01 | -$1.47B 10-Q · filed 2017-11-09 | -$1.52B 10-Q · filed 2016-11-10 | -$1.28B derived: sum of 2 quarters · filed 2017-11-09 | -$1.52B 10-Q · filed 2017-11-09 | -$1.58B 10-Q · filed 2016-11-10 | -$1.62B derived: sum of 4 quarters · filed 2018-03-01 | ||
| 2016-07-02 | $184.80M 10-Q · filed 2017-08-10 | $238.30M 10-Q · filed 2016-08-10 | -$46.80M 10-Q · filed 2017-08-10 | -$65.50M 10-Q · filed 2016-08-10 | -$154.50M derived: sum of 3 quarters · filed 2018-03-01 | $20.80M derived: sum of 4 quarters · filed 2018-03-01 | ||
| 2016-04-02 | -$231.60M 10-Q · filed 2017-05-30 | -$303.80M 10-Q · filed 2016-05-16 | -$339.30M derived: sum of 2 quarters · filed 2018-03-01 | -$164.00M derived: sum of 3 quarters · filed 2018-03-01 | $28.30M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2015-12-31 | -$107.70M derived: 10-K 6 month − 10-Q/A 3 month · filed 2018-03-01 | $67.60M 10-K · filed 2018-03-01 | $94.50M 10-KT · filed 2016-02-25 | $259.90M derived: sum of 3 quarters · filed 2018-03-01 | $450.30M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2015-09-26 | $175.30M 10-Q/A · filed 2017-05-23 | $188.60M 10-Q · filed 2015-11-02 | $367.60M derived: sum of 2 quarters · filed 2017-05-23 | $558.00M 10-Q/A · filed 2017-05-23 | $614.70M 10-Q · filed 2016-11-10 | $742.40M derived: sum of 4 quarters · filed 2017-05-23 | ||
| 2015-06-27 | $192.30M 10-Q/A · filed 2017-05-22 | $226.90M 10-Q · filed 2016-08-10 | $382.70M 10-Q/A · filed 2017-05-22 | $426.20M 10-Q · filed 2016-08-10 | $567.10M derived: sum of 3 quarters · filed 2017-05-22 | $672.50M 10-K · filed 2018-03-01 | $747.70M 10-K · filed 2015-08-13 | |
| 2015-03-28 | $190.40M 10-Q/A · filed 2017-05-22 | $199.20M 10-Q · filed 2015-04-29 | $374.80M derived: sum of 2 quarters · filed 2017-05-22 | $520.70M 10-Q · filed 2015-04-29 | $713.90M derived: sum of 4 quarters · filed 2017-05-22 | |||
| 2014-12-27 | $184.40M 10-Q · filed 2015-02-05 | $289.70M 10-K · filed 2018-03-01 | $321.50M 10-Q · filed 2015-02-05 | $523.50M derived: sum of 3 quarters · filed 2017-05-22 | $626.80M derived: sum of 4 quarters · filed 2017-05-22 | |||
| 2014-09-27 | $137.20M 10-Q · filed 2015-11-02 | $339.10M derived: sum of 2 quarters · filed 2017-05-22 | $442.40M derived: sum of 3 quarters · filed 2017-05-22 | $529.00M derived: sum of 4 quarters · filed 2017-05-22 | ||||
| 2014-06-28 | $201.90M derived: 10-K 12 month − 10-Q 9 month · filed 2017-05-22 | $305.20M derived: sum of 2 quarters · filed 2017-05-22 | $391.80M derived: sum of 3 quarters · filed 2017-05-22 | $571.40M 10-K · filed 2017-05-22 | $567.00M 10-K · filed 2014-08-14 | |||
| 2014-03-29 | $103.30M 10-Q · filed 2015-04-29 | $189.90M derived: sum of 2 quarters · filed 2015-04-29 | $369.50M 10-Q · filed 2015-04-29 | $549.70M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-28 | $86.60M 10-Q · filed 2015-02-05 | $567.00M 10-KT · filed 2016-02-25 | $266.20M 10-Q · filed 2014-02-06 | $446.40M derived: sum of 3 quarters · filed 2016-02-25 | $625.00M derived: sum of 4 quarters · filed 2016-02-25 | |||
| 2013-09-28 | $179.70M 8-K · filed 2014-11-20 | $359.80M derived: sum of 2 quarters · filed 2016-02-25 | $538.40M derived: sum of 3 quarters · filed 2016-02-25 | $702.30M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-06-29 | $180.10M derived: 10-KT 12 month − 10-Q 9 month · filed 2016-02-25 | $358.70M derived: sum of 2 quarters · filed 2016-02-25 | $522.60M derived: sum of 3 quarters · filed 2016-02-25 | $679.10M 10-KT · filed 2016-02-25 | ||||
| 2013-03-30 | $178.60M 10-Q · filed 2014-05-07 | $342.50M derived: sum of 2 quarters · filed 2014-05-07 | $499.00M 10-Q · filed 2014-05-07 | |||||
| 2012-12-29 | $163.90M 10-Q · filed 2014-02-06 | $320.40M 10-Q · filed 2014-02-06 | ||||||
| 2012-06-30 | $569.20M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |